NCT01288391View on ClinicalTrials.gov

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Congenital Bleeding DisorderHaemophilia AHaemophilia B
Interventions
DRUG

NNC 0128-0000-2011

Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)

DRUG

NNC 0128-0000-2011

Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)

Trial Locations (3)

10249

Berlin

28046

Madrid

807-8555

Kitakyushu

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY